Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13
Taysha Gene Therapies (TSHA), a clinical-stage biotechnology company focused on AAV-based gene therapies for CNS diseases, has scheduled its third quarter 2024 financial results release and corporate update conference call for November 13, 2024, at 4:30 PM Eastern Time. The company will discuss its financial performance for the quarter ended September 30, 2024. Investors can access the conference via toll-free and international dial-in numbers or through a webcast on the company's investor relations website.
Taysha Gene Therapies (TSHA), un'azienda biotecnologica in fase clinica focalizzata sulle terapie geniche basate su AAV per malattie del sistema nervoso centrale, ha programmato la sua comunicazione dei risultati finanziari del terzo trimestre 2024 e la relativa conferenza informativa per il 13 novembre 2024, alle 16:30, ora orientale. L'azienda discuterà le sue performance finanziarie per il trimestre concluso il 30 settembre 2024. Gli investitori possono accedere alla conferenza tramite numeri verdi e internazionali o tramite un webcast sul sito web delle relazioni con gli investitori dell'azienda.
Taysha Gene Therapies (TSHA), una empresa de biotecnología en etapa clínica enfocada en terapias génicas basadas en AAV para enfermedades del sistema nervioso central, ha programado su divulgación de resultados financieros del tercer trimestre de 2024 y llamada de actualización corporativa para el 13 de noviembre de 2024, a las 4:30 PM, hora del Este. La empresa discutirá su rendimiento financiero para el trimestre que finalizó el 30 de septiembre de 2024. Los inversores pueden acceder a la conferencia a través de números gratuitos e internacionales o a través de una transmisión en vivo en el sitio web de relaciones con los inversores de la compañía.
Taysha Gene Therapies (TSHA), CNS 질환을 위한 AAV 기반 유전자 치료에 초점을 맞춘 임상 단계의 생명공학 기업,은 2024년 3분기 재무 결과 발표 및 기업 업데이트 컨퍼런스 콜을 2024년 11월 13일, 동부 표준시 오후 4시 30분에 개최할 예정입니다. 이 회사는 2024년 9월 30일로 종료된 분기의 재무 실적에 대해 논의할 것입니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 무료 및 국제적으로 전화 접속하거나 웹캐스트를 통해 컨퍼런스에 참여할 수 있습니다.
Taysha Gene Therapies (TSHA), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies géniques basées sur AAV pour les maladies du système nerveux central, a programmé la diffusion de ses résultats financiers du troisième trimestre 2024 et une conférence de mise à jour d'entreprise pour le 13 novembre 2024 à 16h30, heure de l'Est. L'entreprise discutera de ses performances financières pour le trimestre se terminant le 30 septembre 2024. Les investisseurs peuvent accéder à la conférence via des numéros d'appel gratuits et internationaux ou via un webinaire sur le site internet des relations investisseurs de l'entreprise.
Taysha Gene Therapies (TSHA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf AAV-basierte Gentherapien für Krankheiten des zentralen Nervensystems konzentriert, hat seinen Finanzbericht für das dritte Quartal 2024 und die Unternehmensupdate-Konferenz für den 13. November 2024 um 16:30 Uhr Eastern Time angesetzt. Das Unternehmen wird über seine finanzielle Leistung für das zum 30. September 2024 beendete Quartal berichten. Investoren können die Konferenz über gebührenfreie und internationale Einwahlnummern oder über ein Webcast auf der Investor-Relations-Website des Unternehmens verfolgen.
- None.
- None.
DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2024, and host a corporate update conference call and webcast on Wednesday, November 13, 2024, at 4:30 PM Eastern Time.
Conference Call Details
Wednesday, November 13, at 4:30 PM Eastern Time / 3:30 PM Central Time
Toll Free: 877-407-0792
International: 201-689-8263
Conference ID: 13748703
Webcast: https://ir.tayshagtx.com/news-events/events-presentations
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
carolyn.hawley@inizioevoke.com
FAQ
When will Taysha Gene Therapies (TSHA) report Q3 2024 earnings?
How can investors access TSHA's Q3 2024 earnings call?
What is the conference ID for TSHA's Q3 2024 earnings call?
